INTRODUCTION

The Bevacizumab ELISA kit is designed to measure free Bevacizumab with high specificity and sensitivity. The assay design uses a pair of antibodies allowing detection of whole Bevacizumab molecules in biological matrices. Bevacizumab (Trade name Avastin®) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A(VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.

PRINCIPLE OF THE ASSAY

This assay employs the sandwich enzyme immunoassay technique. Anti-Bevacizumab is coated onto a 96 well microplate. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Bevacizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color devel opment is proportional to the amount of Bevaciuzumab present in test samples.